As Mobidiag's first diagnostic test for respiratory infections, we are focusing all our efforts on diagnostic of the SARS-CoV-2 virus, responsible for the COVID-19 pandemic currently faced globally.
Coronaviruses are a large family of single-stranded RNA viruses that infect mammals and birds, causing respiratory infection. Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2 or SARS-CoV-2) a virus closely related to the SARS virus causes an infectious disease named COVID-19 (novel Coronavirus disease 2019).
The novel coronavirus was first isolated from patients with pneumonia, connected to the cluster of acute respiratory illness cases from Wuhan, China. Genetic analysis revealed that it is closely related to SARS-CoV and genetic clusters within the genus Betacoronavirus, forming a distinct clade in lineage B of the subgenus Sarbecovirus together with two bat-derived SARS-like strains.
Since December 2019, COVID-19 has been spreading rapidly throughout the World and we are proud at Mobidiag to participate in the fight against this pandemic by offering 2 molecular diagnostic tests (now CE-IVD).
Gastrointestinal infections (GI infections) are caused by viral, bacterial or parasitic microorganisms. GI infections are the source of gastroenteritis and inflammation of gastrointestinal tract. The symptoms of which include abdominal pain, vomiting and diarrhea that can lead to potentially dangerous dehydration.
Typical bacterial pathogens in GI infections include E. coli, Salmonella, Shigella and Campylobacter. Viral infections can be caused by norovirus, rotavirus and adenovirus, whilst parasitic infections can stem from a variety of pathogens like Giardia lamblia and Cryptosporidium spp.
GI infections often resolve themselves in a few days without any treatment. However, diagnosis through laboratory tests might be needed in certain cases, for example in healthcare settings when symptoms persist past a reasonable time or in specific patient populations.
Antimicrobial Resistance Management
Antimicrobial resistance (AMR) is a significant and growing global health challenge. The excessive use of antibiotics across the world has boosted the number of multidrug resistant organisms, also called “super bacteria”, making antibiotics less and less effective.
Beta-lactams are by far the most used antibiotics worldwide and include carbapenems which are the most effective against Gram-positive and Gram-negative bacteria. However, during the last decade, Gram-negative bacilli (in particular Enterobacteriaceae) with a decreased susceptibility to carbapenems have been increasingly reported worldwide. There is also a growing resistance to “last resort” antibiotics such as vancomycin and colistin.
Fast diagnosis is key in treating patients with AMR infections. Rapid detection of pathogens and their potential resistance to antibiotics enables faster infection control practices to be implemented, decreases the risk of infection spreading and reduces healthcare costs. Molecular diagnostics offer a much faster method for the diagnosis of AMR, and more extensive screening capabilities.
Healthcare Associated Infections
Nosocomial infections, also called hospital-acquired infections (HAIs) are infections patients acquire in a hospital or other healthcare facility.
The most common types of HAIs include infections following surgeries, urinary tract infections and lower respiratory tract infections. Hospital-acquired gastrointestinal infections are generally caused by bacterial pathogens like Clostridium difficile, Enterobacteriaceae or Staphylococcus aureus.
Hospital-acquired infections occur worldwide both in developed and developing countries. According to the World Health Organization, they are among the prime causes of death and increased morbidity among hospitalized patients.
The economic costs of HAIs are substantial. The prolonged hospital stay they necessitate - together with increased use of medication by the patient and their need for isolation - can lead to considerable costs to patients or healthcare payers.
Sepsis, a potentially life-threatening condition caused by the body's response to an infection is usually treated with antibiotics and large amounts of intravenous fluids. Early detection of sepsis is critical in improving patients’ chances of survival. Sepsis represents a major global health concern affecting more than 30 million people worldwide every year and is responsible for up to 6 million deaths every year(1).
Supported by Business Finland, Mobidiag is currently developing a revolutionary assay to detect sepsis causing microbes and antibiotic resistances. Mobidiag is harnessing the power of its Novodiag® platform to develop a fast, simple and reliable syndromic assay to detect sepsis within a couple of hours, directly from a patient’s blood sample. Mobidiag has previous experience in developing a diagnostic test for sepsis, its former Prove-it product which was able to detect 80 targets simultaneously from blood cultures.
Learn more about our latest announcement and development.